 |
31 |
 |
| |
Pharmacologic Strategies
|
|
 |
|
 |
|
|
32 |
|
| |
Currently approved pharmacologic options for long-term weight management
|
|
|
|
|
|
|
33 |
|
| |
Weight loss with orlistat: Meta-analysis
|
|
|
|
|
|
|
34 |
|
| |
Orlistat: Change in cardiometabolic parameters
|
|
|
|
|
|
|
35 |
|
| |
Weight loss with sibutramine: Meta-analysis
|
|
|
|
|
|
|
36 |
|
| |
Sibutramine: Change in cardiometabolic parameters
|
|
|
|
|
|
|
37 |
|
| |
New targets for weight loss and cardiometabolic risk reduction
|
|
|
|
|
|
|
38 |
|
| |
Exenatide: Effects on weight
|
|
|
|
|
|
|
39 |
|
| |
Pramlintide: Effects on weight
|
|
|
|
|
|
|
40 |
|
| |
Pramlintide plus recombinant leptin for weight loss: Pilot study
|
|
|
|
|
|
|
41 |
|
| |
New systems targeting cardiometabolic risk reduction: Summary
|
|
|
|
|
|
|
Resources
